Nucana PLC (NCNA) — 6-K Filings

6-K Filings (38)

• 6-K Filing — Dec 17, 2025
• NuCana plc Presents New Clinical Data — Dec 10, 2025 Risk: low
  On December 10, 2025, NuCana plc announced the presentation of new clinical data from patients treated with their drug. The press release was filed as a Form 6-
• NuCana plc Reports Q3 2025 Financial Results — Nov 13, 2025 Risk: low
  NuCana plc announced its third quarter 2025 financial results on November 13, 2025. The company, formerly known as NuCana BioMed Ltd, is a pharmaceutical prepar
• 6-K Filing — Nov 5, 2025
• NuCana plc Presents New ProTide Technology Data — Oct 20, 2025 Risk: low
  On October 18, 2025, NuCana plc announced the presentation of data from a new model system investigating the potential of its ProTide technology. This presentat
• NuCana plc Publishes New Data from NuTide:303 Study — Oct 14, 2025 Risk: medium
  On October 14, 2025, NuCana plc announced the publication of new data from its NuTide:303 clinical study. The study focuses on the company's ProTide technology,
• NuCana plc Confirms Compliance with Credit Facility Covenants — Sep 5, 2025 Risk: low
  On September 5, 2025, NuCana plc announced it is in compliance with all applicable covenants under its credit facility. This filing is a Form 6-K, a report of a
• NuCana to Present Pancreatic Cancer Data at ESMO — Sep 3, 2025 Risk: medium
  On September 3, 2025, NuCana plc announced it will present at the European Society for Medical Oncology (ESMO) Congress 2025. The presentation will feature data
• NuCana plc Files 6-K Report for Q2 2025 — Aug 20, 2025 Risk: low
  NuCana plc filed a 6-K report on August 20, 2025, detailing financial information for the period ending June 30, 2025. The filing includes financial statements
• NuCana plc Announces ADS Ratio Change — Aug 1, 2025 Risk: low
  On August 1, 2025, NuCana plc announced it will implement a previously disclosed plan to change its American Depositary Share (ADS) ratio. This action is part o
• NuCana plc Cancels Series A Warrants — Jul 21, 2025 Risk: medium
  On July 21, 2025, NuCana plc announced the cancellation of all outstanding Series A ADS Purchase Warrants. This action was taken following a strategic At-the-Ma
• NuCana plc Plans ADS Ratio Change — Jul 11, 2025 Risk: low
  On July 11, 2025, NuCana plc announced its intention to change the ratio of its American Depositary Shares (ADSs). This filing is a Form 6-K, a report of a fore
• NuCana plc Receives Nasdaq Non-Compliance Notice — Jul 9, 2025 Risk: medium
  NuCana plc announced on July 9, 2025, that it received a written notice from Nasdaq on June 18, 2025, regarding its non-compliance with listing requirements. Th
• NuCana plc Secures $50M Sales Agreement — Jun 30, 2025 Risk: medium
  On June 27, 2025, NuCana plc entered into a Sales Agreement with A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. This agreement allows NuCana to
• NuCana plc Cancels Warrants via Letter Agreements — Jun 27, 2025 Risk: low
  NuCana plc announced on June 27, 2025, that it has entered into letter agreements with holders of its warrants to cancel these warrants. This action is part of
• NuCana plc Faces Nasdaq Delisting Warning — Jun 20, 2025 Risk: medium
  On June 18, 2025, NuCana plc received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC. This notification indica
• NuCana CEO Hugh S. Griffith Takes Health Leave — Jun 18, 2025 Risk: medium
  NuCana plc announced on June 18, 2025, that its Chief Executive Officer, Hugh S. Griffith, is taking a leave of absence due to health reasons. The company has n
• NuCana plc Releases 2024 UK Annual Report — Jun 5, 2025 Risk: low
  On June 5, 2025, NuCana plc published its 2024 UK Annual Report. The report covers the company's performance for the year ended December 31, 2024. NuCana plc is
• NuCana plc Files Q1 2025 Financial Results — Jun 2, 2025 Risk: low
  NuCana plc announced its first quarter 2025 financial results on June 2, 2025. The filing is a Form 6-K, which is a report of a foreign issuer. The company is b
• NuCana plc Files 6-K Report, Holds General Meeting — Apr 23, 2025 Risk: low
  On April 23, 2025, NuCana plc held a General Meeting (GM) at Lochside House, Edinburgh, UK. The company is a foreign issuer filing a Form 6-K report with the SE
• NuCana plc Reports 2024 Financial Results — Mar 20, 2025 Risk: low
  NuCana plc announced its financial results for the year ended December 31, 2024, on March 20, 2025. The company, headquartered in Edinburgh, United Kingdom, is
• NuCana plc Announces General Meeting for April 7 — Mar 18, 2025 Risk: low
  NuCana plc announced on March 18, 2025, that it will hold a general meeting on April 7, 2025. The company, previously known as NuCana BioMed Ltd, is a pharmaceu
• NuCana plc CFO Departs — Feb 10, 2025 Risk: medium
  NuCana plc announced the departure of its Chief Financial Officer, Donald Munoz, effective February 7, 2025. The company, based in Edinburgh, United Kingdom, fi
• NuCana plc Reports Q3 2024 Financial Results — Nov 25, 2024 Risk: low
  NuCana plc announced its third quarter 2024 financial results on November 25, 2024. The filing does not provide specific dollar amounts or detailed financial fi
• NuCana plc Releases Initial Phase 1 Trial Data — Nov 12, 2024 Risk: medium
  NuCana plc announced on November 11, 2024, the publication of initial data from its ongoing Phase 1 clinical trial. The press release details the results of thi
• NuCana plc Amends Prospectus Supplement — Oct 1, 2024 Risk: low
  On September 30, 2024, NuCana plc amended its Prospectus Supplement originally dated August 27, 2021. This filing is a routine update for the month of September
• NuCana plc Secures New US Patent for ProTide Technology — Sep 26, 2024 Risk: low
  NuCana plc announced on September 25, 2024, that it has been issued a new patent (US12,0) for its ProTide technology. This patent is expected to strengthen the
• NuCana plc Presents Final Phase 2 NuTide Data — Sep 16, 2024 Risk: medium
  NuCana plc announced on September 14, 2024, the presentation of final data from its Phase 2 NuTide study. The study focused on the treatment of patients with bi
• NuCana plc Discontinues NuTide:323 Study — Aug 29, 2024 Risk: medium
  NuCana plc announced on August 29, 2024, that it is discontinuing the NuTide:323 study. This decision was made following a review of the study's progress and da
• NuCana plc Files 6-K for Q2 2024 Financials — Aug 15, 2024 Risk: low
  NuCana plc filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the second quarter of 2024, comparing it to the same p
• NuCana plc Holds Annual General Meeting — Jun 18, 2024 Risk: low
  NuCana plc held its Annual General Meeting (AGM) on June 18, 2024, at Lochside House in Edinburgh. The company, which is involved in pharmaceutical preparations
• NuCana plc Files Q1 2024 Financial Results — May 16, 2024 Risk: low
  NuCana plc announced its first quarter 2024 financial results on May 16, 2024. The filing is a Form 6-K, which is a report of a foreign issuer. Specific financi
• NuCana plc Releases 2023 UK Annual Report — May 13, 2024 Risk: low
  NuCana plc published its 2023 UK Annual Report on May 13, 2024. The report covers the company's performance for the year ended December 31, 2023. NuCana plc is
• NuCana plc Faces Nasdaq Delisting Warning — May 1, 2024 Risk: medium
  NuCana plc announced on May 1, 2024, that it received written notification from The Nasdaq Stock Market regarding its non-compliance with the minimum bid price
• NuCana plc Completes ADS Ratio Change — Apr 16, 2024 Risk: low
  NuCana plc announced on April 16, 2024, the completion of its previously disclosed American Depositary Share (ADS) ratio change. This change adjusts the number
• NuCana plc Presents NUC-7738 Data at AACR Meeting — Apr 9, 2024 Risk: medium
  On April 9, 2024, NuCana plc announced the presentation of two posters detailing NUC-7738 at the American Association for Cancer Research (AACR) Annual Meeting.
• NuCana plc to Change ADS Ratio to Meet Nasdaq Listing Requirements — Mar 27, 2024 Risk: medium
  NuCana plc announced on March 27, 2024, a plan to change the ratio of its American Depositary Shares (ADSs). This change is intended to adjust the number of ord
• NuCana plc Reports 2023 Financial Results — Mar 20, 2024 Risk: low
  NuCana plc announced its financial results for the year ended December 31, 2023, on March 20, 2024. The company, headquartered in Edinburgh, United Kingdom, is

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX